Abstract
Introduction: Potassium-competitive acid blockers are effective against proton pump inhibitor-refractory gastroesophageal reflux disease; however, their long-term use is associated with economic disadvantages. Endoscopic procedures may reduce potassium-competitive acid blocker use. This study aimed to determine the optimal treatment strategy for patients with proton pump inhibitor-refractory gastroesophageal reflux disease from a cost-effectiveness perspective. Methods: Using a Markov state transition model to simulate symptom changes in patients with proton pump inhibitor-refractory gastroesophageal reflux disease, the cost-effectiveness of two strategies was compared: endoscopic treatment (anti-reflux mucosectomy or endoscopic submucosal dissection for gastroesophageal reflux disease) followed by potassium-competitive acid blocker versus medication with high-dose potassium-competitive acid blocker. In both strategies, potassium-competitive acid blocker maintained symptoms at the lowest controllable dose. The time horizon varied from 10 to 50 years. The quality-adjusted life year and incremental cost-effectiveness ratio were calculated. Willingness to pay was set at 5,000,000 Japanese yen. Results: The quality-adjusted life years gained were 0.90 and 0.95 for the endoscopic treatment and medication strategies, respectively. The incremental cost-effectiveness ratio varied with the follow-up period after the initial treatment, with the endoscopic treatment strategy being more cost-effective than the medication strategy at ≥50 years of follow-up. A dose reduction success rate of <84.1% for high-dose potassium-competitive acid blocker and an endoscopic treatment success rate of >66.8% were required to determine the superiority of the endoscopic treatment strategy at the 50-year follow-up after treatment. Conclusions: The endoscopic treatment strategy is not cost-effective unless the patient is followed up for >50 years after the initial treatment.
Journal Section:
Research Article
References
1.
Eusebi
LH
, Ratnakumaran
R
, Yuan
Y
, Solaymani-Dodaran
M
, Bazzoli
F
, Ford
AC
. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
. Gut
. 2018
;67
(3
):430
–40
. 2.
Kinoshita
Y
, Adachi
K
, Hongo
M
, Haruma
K
. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan
. J Gastroenterol
. 2011
;46
(9
):1092
–103
. 3.
Hojo
M
, Nagahara
A
, Hahm
K-B
, Iwakiri
R
, Watanabe
T
, Rani
AA
, et al. Management of gastroesophageal reflux disease in Asian countries: results of a questionnaire survey
. Digestion
. 2020
;101
(1
):66
–79
. 4.
Saha
B
, Vantanasiri
K
, Mohan
BP
, Goyal
R
, Garg
N
, Gerberi
D
, et al. Prevalence of Barrett’s esophagus and esophageal adenocarcinoma with and without gastroesophageal reflux: a systematic review and meta-analysis
. Clin Gastroenterol Hepatol
. 2024
;22
(7
):1381
–94.e7
. 5.
Katz
PO
, Dunbar
KB
, Schnoll-Sussman
FH
, Greer
KB
, Yadlapati
R
, Spechler
SJ
. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease
. Am J Gastroenterol
. 2022
;117
(1
):27
–56
. 6.
Becher
A
, El-Serag
H
. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease
. Aliment Pharmacol Ther
. 2011
;34
(6
):618
–27
. 7.
Fass
R
, Sontag
SJ
, Traxler
B
, Sostek
M
. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial
. Clin Gastroenterol Hepatol
. 2006
;4
(1
):50
–6
. 8.
Fass
R
, Murthy
U
, Hayden
CW
, Malagon
IB
, Pulliam
G
, Wendel
C
, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study
. Aliment Pharmacol Ther
. 2000
;14
(12
):1595
–603
. 9.
Kunsch
S
, Neesse
A
, Linhart
T
, Nell
C
, Gress
TM
, Ellenrieder
V
. Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy
. Digestion
. 2012
;86
(4
):315
–22
. 10.
Jenkins
H
, Sakurai
Y
, Nishimura
A
, Okamoto
H
, Hibberd
M
, Jenkins
R
, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
. Aliment Pharmacol Ther
. 2015
;41
(7
):636
–48
. 11.
Sakurai
Y
, Mori
Y
, Okamoto
H
, Nishimura
A
, Komura
E
, Araki
T
, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study
. Aliment Pharmacol Ther
. 2015
;42
(6
):719
–30
. 12.
Kagami
T
, Sahara
S
, Ichikawa
H
, Uotani
T
, Yamade
M
, Sugimoto
M
, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
. Aliment Pharmacol Ther
. 2016
;43
(10
):1048
–59
. 13.
Iwakiri
K
, Fujiwara
Y
, Manabe
N
, Ihara
E
, Kuribayashi
S
, Akiyama
J
, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021
. J Gastroenterol
. 2022
;57
(4
):267
–85
. 14.
Zhuang
Q
, Chen
S
, Zhou
X
, Jia
X
, Zhang
M
, Tan
N
, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C/D esophagitis: a systematic review and network meta-analysis
. Am J Gastroenterol
. 2024
;119
(5
):803
–13
. 15.
Abe
Y
, Koike
T
, Saito
M
, Okata
T
, Nakagawa
K
, Hatta
W
, et al. The ameliorating effect of switching to vonoprazan: a novel potassium-competitive acid blocker in patients with proton pump inhibitor refractory non-erosive reflux disease
. Digestion
. 2021
;102
(3
):480
–8
. 16.
Akiyama
J
, Hosaka
H
, Kuribayashi
S
, Moriyasu
S
, Hisada
Y
, Okubo
H
, et al. Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux
. Digestion
. 2020
;101
(2
):174
–83
. 17.
Tanabe
T
, Hoshino
S
, Kawami
N
, Hoshikawa
Y
, Hanada
Y
, Takenouchi
N
, et al. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis
. Esophagus
. 2019
;16
(4
):377
–81
. 18.
Miwa
H
, Shiotani
A
, Takeda
M
, Eda
M
, Kato
T
, Yajima
T
. Health care cost analysis of PPI or P-CAB-first treatment in patients with gastroesophageal reflux disease
. J Clin Gastroenterol
. 2023
;57
(4
):370
–9
. 19.
Simadibrata
DM
, Lesmana
E
, Fass
R
. Role of endoscopy in gastroesophageal reflux disease
. Clin Endosc
. 2023
;56
(6
):681
–92
. 20.
Lee
AY
, Kim
SH
, Cho
JY
. Comparative evaluation of endoscopic anti-reflux mucosectomy and stretta radiofrequency ablation in the management of gastroesophageal reflux disease: insights from a retrospective multicenter cohort study
. Surg Endosc
. 2024
;38
(8
):4278
–86
. 21.
Kuipers
T
, Oude Nijhuis
RAB
, Pouw
RE
, Bredenoord
AJ
. Antireflux mucosectomy for gastroesophageal reflux disease: efficacy and the mechanism of action
. Endoscopy
. 2024
;56
(12
):897
–905
. 22.
Lee
YS
, Kim
JH
, Yon
DK
, Yoo
IK
. Short and long term effect of anti-reflux mucosectomy with cap-assisted endoscopic mucosal resection for refractory gastroesophageal disease
. Surg Endosc
. 2024
;38
(4
):2180
–7
. 23.
Hu
JN
, Chen
SF
, Jia
XY
, Luo
Y
, Xing
XB
, Tan
ND
, et al. Two-year outcomes of anti-reflux mucosectomy in treating gastroesophageal reflux disease: a Chinese prospective cohort study
. J Dig Dis
. 2023
;24
(11
):611
–8
. 24.
Sumi
K
, Inoue
H
, Ando
R
, Fujiyoshi
MRA
, Fujiyoshi
Y
, Tanabe
M
, et al. Long-term efficacy of antireflux mucosectomy in patients with refractory gastroesophageal reflux disease
. Dig Endosc
. 2024
;36
(3
):305
–13
. 25.
Chou
C-K
, Chen
C-C
, Chen
C-C
, Wu
J-F
, Liao
W-C
, Chiu
H-M
, et al. Positive and negative impact of anti-reflux mucosal intervention on gastroesophageal reflux disease
. Surg Endosc
. 2023
;37
(2
):1060
–9
. 26.
Sui
X
, Gao
X
, Zhang
L
, Zhang
B
, Zhong
C
, Chen
Y
, et al. Clinical efficacy of endoscopic antireflux mucosectomy vs. Stretta radiofrequency in the treatment of gastroesophageal reflux disease: a retrospective, single-center cohort study
. Ann Transl Med
. 2022
;10
(12
):660
. 27.
Ota
K
, Takeuchi
T
, Kojima
Y
, Sugawara
N
, Nishida
S
, Iwatsubo
T
, et al. Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5 years
. BMC Gastroenterol
. 2021
;21
(1
):432
. 28.
Ishibashi
F
, Suzuki
S
, Kobayashi
K
, Tanaka
R
, Kawakami
T
, Mochida
K
, et al. Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment
. J Gastroenterol Hepatol
. 2024
;39
(7
):1328
–35
. 29.
Simadibrata
DM
, Lesmana
E
, Fass
R
. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease
. J Gastroenterol Hepatol
. 2024
;39
(5
):796
–805
. 30.
Shinozaki
S
, Osawa
H
, Miura
Y
, Sakamoto
H
, Hayashi
Y
, Yano
T
, et al. The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study
. Scand J Gastroenterol
. 2024
;59
(8
):893
–9
. 31.
Okanobu
H
, Kohno
T
, Boda
K
, Ochi
H
, Furukawa
Y
. Long-term clinical course after successful initial treatment in patients with mild erosive esophagitis: a prospective follow-up study
. Digestion
. 2023
;104
(4
):283
–90
. 32.
Tanaka
H
, Takeuchi
T
, Nishida
S
, Hongo
H
, Takii
M
, Higashino
T
, et al. Examination on factors affecting symptom change after drug withdrawal in patients with mild erosive gastroesophageal reflux disease undergoing symptom-controlled maintenance therapy with acid-secretion inhibition drugs
. Digestion
. 2023
;104
(4
):270
–82
. 33.
Mizuno
H
, Yamada
K
, Minouchi
K
, Kamiyamamoto
S
, Hinoue
Y
. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors
. Biomed Rep
. 2018
;8
(2
):148
–55
. 34.
Gotoh
Y
, Ishibashi
E
, Honda
S
, Nakaya
T
, Noguchi
C
, Kagawa
K
, et al. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
. Medicine
. 2020
;99
(11
):e19520
. 35.
Hoshino
S
, Kawami
N
, Takenouchi
N
, Umezawa
M
, Hanada
Y
, Hoshikawa
Y
, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis
. Digestion
. 2017
;95
(2
):156
–61
. 36.
Bojke
L
, Hornby
E
, Sculpher
M
; REFLUX Trial Team
. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD
. Pharmacoeconomics
. 2007
;25
(10
):829
–41
. 37.
Szende
A
, Janssen
B
, Cabases
J
, editors. Self-reported population health: an international perspective based on EQ-5D
. Dordrecht, Netherlands
: Springer
; 2016
.38.
Harper
S
, Kartha
M
, Mealing
S
, Borbély
YM
, Zehetner
J
. Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland
. J Med Econ
. 2024
;27
(1
):805
–15
. 39.
Park
S
, Park
S
, Park
J-M
, Ryu
S
, Hwang
J
, Kwon
J-W
, et al. Anti-reflux surgery versus proton pump inhibitors for severe gastroesophageal reflux disease: a cost-effectiveness study in Korea
. J Neurogastroenterol Motil
. 2020
;26
(2
):215
–23
. 40.
Harper
S
, Grodzicki
L
, Mealing
S
, Gemmill
L
, Goldsmith
PJ
, Ahmed
AR
. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease
. J Med Econ
. 2023
;26
(1
):603
–13
. 41.
Comay
D
, Adam
V
, da Silveira
EB
, Kennedy
W
, Mayrand
S
, Barkun
AN
. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis
. Can J Gastroenterol
. 2008
;22
(6
):552
–8
. 42.
Habu
Y
, Hamasaki
R
, Maruo
M
, Nakagawa
T
, Aono
Y
, Hachimine
D
. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: a cost-effectiveness analysis in Japan
. J Gen Fam Med
. 2021
;22
(5
):237
–45
. 43.
Ashida
K
, Sakurai
Y
, Hori
T
, Kudou
K
, Nishimura
A
, Hiramatsu
N
, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
. Aliment Pharmacol Ther
. 2016
;43
(2
):240
–51
. 44.
Ashida
K
, Iwakiri
K
, Hiramatsu
N
, Sakurai
Y
, Hori
T
, Kudou
K
, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole
. World J Gastroenterol
. 2018
;24
(14
):1550
–61
. 45.
Uemura
N
, Kinoshita
Y
, Haruma
K
, Kushima
R
, Yao
T
, Akiyama
J
, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study
. Clin Gastroenterol Hepatol
. 2024
. 46.
Kojima
Y
, Takeuchi
T
, Sanomura
M
, Higashino
K
, Kojima
K
, Fukumoto
K
, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study
. Digestion
. 2018
;97
(1
):70
–5
. 47.
Shinozaki
S
, Osawa
H
, Miura
Y
, Hayashi
Y
, Sakamoto
H
, Yano
T
, et al. Long-term changes in serum gastrin levels during standard dose vonoprazan therapy
. Scand J Gastroenterol
. 2022
;57
(12
):1412
–6
. 48.
Song
H
, Zhu
J
, Lu
D
. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions
. Cochrane Database Syst Rev
. 2014
;2014
(12
):CD010623
. 49.
Inoue
H
, Yamamoto
K
, Shimamura
Y
, Azuma
D
, Ushikubo
K
, Okada
H
, et al. Pilot study on anti-reflux mucoplasty: advancing endoscopic anti-reflux therapy for gastroesophageal reflux disease
. Dig Endosc
. 2024
;36
(6
):690
–8
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
